1.Platelet RNA signature independently predicts ovarian cancer prognosis by deep learning neural network model.
Chun-Jie LIU ; Hua-Yi LI ; Yue GAO ; Gui-Yan XIE ; Jian-Hua CHI ; Gui-Ling LI ; Shao-Qing ZENG ; Xiao-Ming XIONG ; Jia-Hao LIU ; Lin-Li SHI ; Xiong LI ; Xiao-Dong CHENG ; Kun SONG ; Ding MA ; An-Yuan GUO ; Qing-Lei GAO
Protein & Cell 2023;14(8):618-622
2.Different imprinting status of IGF-2 in epithelial ovarian tumors.
Yali, XIONG ; Yongyu, SUN ; Hongfa, LI
Journal of Huazhong University of Science and Technology (Medical Sciences) 2002;22(3):255-6
To explore whether the imprinting status of IGF-2 in the malignant epithelial ovarian tumors is different from that in benign tumors, the target sequences (DNA and RNA) which contain a polymorphism site for ApaI restriction endonuclease digestion were amplified with PCR and RT-PCR methods. Then the PCR/RT-PCR products were digested by ApaI. The IGF-2 transcriptional pattern came out from the results of endonucleases digestion. Among the 36 cases of benign epithelial ovarian tumors, 20 were heterozygous for ApaI locus and all showed genomic imprinting. While in the malignant group, 22 were heterozygous for ApaI locus but six were found to lose imprinting. Significant differences existed between the two groups (P < 0.05). Loss of imprinting of IGF-2 may serve as a marker for differentiating the malignant ovarian cancers from the benign ones. In a new field of molecular genetics, our research provides an experimental basis for genetic diagnosis and treatment of the ovarian cancers.
Cystadenocarcinoma, Serous/*genetics
;
Cystadenoma/genetics
;
*Genomic Imprinting
;
Insulin-Like Growth Factor II/*genetics
;
Ovarian Neoplasms/*genetics
3.Progress in studies on the relationship between Dicer and ovarian tumor.
Hua ZHAO ; Huajiang SHAO ; Jianting MA
Journal of Central South University(Medical Sciences) 2015;40(10):1156-1160
MiRNAs are short, noncoding RNAs that modulate gene expression at the posttranscriptional level and induce the degradation of the mRNA transcript or the inhibition of protein translation. Dicer is an endoribonuclease in the RNase III family that is essential for the production of miRNAs. The abnormal expression of Dicer is frequently found in the occurrence and development process of many kinds of tumors, which is closely related to the treatment and prognosis of tumor.
DEAD-box RNA Helicases
;
genetics
;
Female
;
Humans
;
MicroRNAs
;
genetics
;
Ovarian Neoplasms
;
genetics
;
Prognosis
;
Ribonuclease III
;
genetics
4.Ovarian cancer: a molecularly insidious disease.
Chinese Journal of Cancer 2015;34(1):1-3
In this issue of the Chinese Journal of Cancer, European, American, and Chinese experts review the current management and future perspectives of epithelial ovarian cancer (EOC), the leading cause of gynecological cancer deaths. Although major advances have been made in understanding the cellular and molecular biology of this highly heterogeneous malignancy, the survival rate of women with EOC has changed little since the introduction of platinum-based treatment as a front-line therapy. The papers describe the progress in deciphering the molecular complexity of this disease and the newly available molecular-driven therapies, which have been applied by shifting trial designs toward restricting eligibility to specific subgroups of patients rather than testing agents in unselected populations. These new trial designs provide potential opportunities for improved efficacy in targeted populations. Given the molecular complexity of this disease, patient survival may be increased by searching for new molecular prognostic/predictive signatures as well as by translating the recent insight of microRNA involvement in EOC progression into new, targeted therapies. Particular attention has been given to the issue of fertility sparing for women affected by curable diseases.
Female
;
Humans
;
MicroRNAs
;
physiology
;
Neoplasms, Glandular and Epithelial
;
drug therapy
;
genetics
;
Ovarian Neoplasms
;
drug therapy
;
genetics
6.Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer.
Tiffany LAI ; Bruce KESSEL ; Hyeong Jun AHN ; Keith Y TERADA
Journal of Gynecologic Oncology 2016;27(4):e41-
OBJECTIVE: To determine whether annual screening reduces ovarian cancer mortality in women with a family history of breast or ovarian cancer. METHODS: Data was obtained from the Prostate, Lung, Colorectal, and Ovarian cancer trial, a randomized multi-center trial conducted to determine if screening could reduce mortality in these cancers. The trial enrolled 78,216 women, randomized into either a screening arm with annual serum cancer antigen 125 and pelvic ultrasounds, or usual care arm. This study identified a subgroup that reported a first degree relative with breast or ovarian cancer. Analysis was performed to compare overall mortality and disease specific mortality in the screening versus usual care arm. In patients diagnosed with ovarian cancer, stage distribution, and survival were analyzed as a secondary endpoint. RESULTS: There was no significant difference in overall mortality or disease specific mortality between the two arms. Ovarian cancer was diagnosed in 48 patients in the screening arm and 44 patients in the usual care arm. Screened patients were more likely to be diagnosed at an earlier stage than usual care patients. Patients in the screening arm diagnosed with ovarian cancer experienced a significantly improved survival compared to patients in the usual care arm; relative risk 0.66 (95% CI, 0.47 to 0.93). CONCLUSION: Screening did not appear to decrease ovarian cancer mortality in participants with a family history of breast or ovarian cancer. Secondary endpoints, however, showed notable differences. Significantly fewer patients were diagnosed with advanced stage disease in the screening arm; and survival was significantly improved. Further investigation is warranted to assess screening efficacy in women at increased risk.
Aged
;
Breast Neoplasms/*genetics
;
*Early Detection of Cancer
;
Female
;
Humans
;
Menopause
;
Middle Aged
;
Ovarian Neoplasms/diagnosis/*genetics
7.Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer.
Tiffany LAI ; Bruce KESSEL ; Hyeong Jun AHN ; Keith Y TERADA
Journal of Gynecologic Oncology 2016;27(4):e41-
OBJECTIVE: To determine whether annual screening reduces ovarian cancer mortality in women with a family history of breast or ovarian cancer. METHODS: Data was obtained from the Prostate, Lung, Colorectal, and Ovarian cancer trial, a randomized multi-center trial conducted to determine if screening could reduce mortality in these cancers. The trial enrolled 78,216 women, randomized into either a screening arm with annual serum cancer antigen 125 and pelvic ultrasounds, or usual care arm. This study identified a subgroup that reported a first degree relative with breast or ovarian cancer. Analysis was performed to compare overall mortality and disease specific mortality in the screening versus usual care arm. In patients diagnosed with ovarian cancer, stage distribution, and survival were analyzed as a secondary endpoint. RESULTS: There was no significant difference in overall mortality or disease specific mortality between the two arms. Ovarian cancer was diagnosed in 48 patients in the screening arm and 44 patients in the usual care arm. Screened patients were more likely to be diagnosed at an earlier stage than usual care patients. Patients in the screening arm diagnosed with ovarian cancer experienced a significantly improved survival compared to patients in the usual care arm; relative risk 0.66 (95% CI, 0.47 to 0.93). CONCLUSION: Screening did not appear to decrease ovarian cancer mortality in participants with a family history of breast or ovarian cancer. Secondary endpoints, however, showed notable differences. Significantly fewer patients were diagnosed with advanced stage disease in the screening arm; and survival was significantly improved. Further investigation is warranted to assess screening efficacy in women at increased risk.
Aged
;
Breast Neoplasms/*genetics
;
*Early Detection of Cancer
;
Female
;
Humans
;
Menopause
;
Middle Aged
;
Ovarian Neoplasms/diagnosis/*genetics
8.Research Progress of MicroRNA in Early Detection of Ovarian Cancer.
Chinese Medical Journal 2015;128(24):3363-3370
OBJECTIVEThis review aimed to update the progress of microRNA (miRNA) in early detection of ovarian cancer. We discussed the current clinical diagnosis methods and biomarkers of ovarian cancer, especially the methods of miRNA in early detection of ovarian cancer.
DATA SOURCESWe collected all relevant studies about miRNA and ovarian cancer in PubMed and CNKI from 1995 to 2015.
STUDY SELECTIONWe included all relevant studies concerning miRNA in early detection of ovarian cancer, and excluded the duplicated articles.
RESULTSmiRNAs play a key role in various biological processes of ovarian cancer, such as development, proliferation, differentiation, apoptosis and metastasis, and these phenomena appear in the early-stage. Therefore, miRNA can be used as a new biomarker for early diagnosis of ovarian cancer, intervention on miRNA expression of known target genes, and potential target genes can achieve the effect of early prevention. With the development of nanoscience and technology, analysis methods of miRNA are also quickly developed, which may provide better characterization of early detection of ovarian cancer.
CONCLUSIONSIn the near future, miRNA therapy could be a powerful tool for ovarian cancer prevention and treatment, and combining with the new analysis technology and new nanomaterials, point-of-care tests for miRNA with high throughput, high sensitivity, and strong specificity are developed to achieve the application of diagnostic kits in screening of early ovarian cancer.
Early Detection of Cancer ; methods ; Female ; Gene Expression Regulation, Neoplastic ; genetics ; Humans ; MicroRNAs ; genetics ; Ovarian Neoplasms ; genetics
9.Mutations in the D-loop region of mitochondrial DNA in ovarian tumors.
Hong-hui SHI ; Liu VINCENT ; Ngan HEXTAN ; Xiu-yu YANG
Acta Academiae Medicinae Sinicae 2002;24(2):170-173
OBJECTIVETo investigate mutations in the D-loop region of mitochondrial DNA in ovarian tumors.
METHODSThe D-loop region of 25 epithelial ovarian tumors together with the adjacent normal tissues were amplified by PCR and sequenced.
RESULTSAmong the 25 ovarian tumors, 26 mutations were identified with the mutation rate of 32%. 19 mutations were detected in two cases of borderline carcinoma which was a special type of epithelial ovarian carcinoma. There were 6 microsatellite instabilities among the mutations and 11 new polymorphisms which were not reported previously in the GenBank.
CONCLUSIONSThe D-loop region of mitochondrial DNA is a highly polymorphoric and mutable region and the mutation rate is relatively high in patients with ovarian tumors.
Cystadenocarcinoma, Serous ; genetics ; DNA, Mitochondrial ; genetics ; Female ; Humans ; Ovarian Neoplasms ; genetics ; Point Mutation ; Polymorphism, Genetic
10.Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis.
Pan Yang ZHANG ; Ming Mei HE ; Yuan Yuan ZENG ; Xiong Wei CAI
Journal of Southern Medical University 2023;43(1):8-16
OBJECTIVE:
To investigate the correlation of the potential functional microRNA (miRNA)-mRNA regulatory network with recurrence of high-grade serous ovarian carcinoma (HGSOC) and its biological significance.
METHODS:
This study was performed based on the data of 354 patients with HGSOC from the Cancer Genome Atlas database. In these patients, HGSOC was divided into different subtypes based on the pathways identified by GO analysis, and the correlations of the subtypes with HGSOC recurrence and differentially expressed miRNAs and mRNAs were assessed. Two relapse-related datasets were identified using the Gene Set Enrichment (GSE) database, from which the differentially expressed miRNAs were identified by intersection with the TCGA data. The target genes of these miRNAs were predicted using miRWalk 2.0 database, and these common differentially expressed miRNAs and mRNAs were used to construct the key miRNA-mRNA network associated with HGSOC recurrence. The expression of miR-506-3p and SNAI2 in two ovarian cancer cell lines was detected using RT-qPCR and Western blotting, and their targeted binding was verified using a double luciferase assay. The effect of miR-506-3p expression modulation on ovarian cancer cell migration was detected using scratch assay and Transwell assay.
RESULTS:
We screened 303 GO terms of HGSOC-related pathways and identified two HGSOC subtypes (C1 and C2). The subtype C1 was associated with a significantly higher recurrence rate than C2. The differentially expressed genes between C1 and C2 subtypes were mainly enriched in epithelial-mesenchymal transition (EMT). Five miRNAs were identified as potential regulators of EMT, and a total of 41 target genes were found to be involved in the differential expressions of EMT pathway between C1 and C2 subtypes. The key miRNA-mRNA network associated with HGSOC recurrence was constructed based on these 5 miRNAs and 41 mRNAs. MiR-506-3p was confirmed to bind to SNAI2, and up-regulation of miR-506-3p significantly inhibited SNAI2 expression and reduced migration and invasion of SKOV3 and CAOV3 cells (P < 0.05), while miR-506-3p knockdown produced the opposite effects (P < 0.05).
CONCLUSION
MiR-506-3p and SNAI2 are the key molecules associated with HGSOC recurrence. MiR-506-3p may affect EMT of ovarian cancer cells by regulating cell migration and invasion via SNAI2, and its expression level has predictive value for HGSOC recurrence.
Humans
;
Female
;
MicroRNAs/genetics*
;
Neoplasm Recurrence, Local/genetics*
;
Ovarian Neoplasms/genetics*
;
Computational Biology